CNS Spectrums
July 11, 2022
Seetal Dodd, Trevor R. Norman, Harris A. Eyre et al.
61 citations
Psilocybin, a tryptamine alkaloid found in Psilocybe mushrooms, is metabolized into the active compound psilocin, which produces psychoactive effects primarily by partially activating the 5HT2A receptor. Psilocin also binds to other receptor subtypes, though these actions are not fully understood. Clinical trials have tested psilocybin at hallucinogenic doses for addictive disorders, anxiety, and depression. This review assesses psilocybin and psilocin as potential neuropsychiatric treatments, weighing therapeutic benefits against potential harms. The authors conclude that careful evaluation of the number needed to harm versus the number needed to treat will determine clinical viability, and they call for a responsible path forward in this field.
Expert opinion on emerging drugs
June 1, 2025
Maria-Alejandra Umbacia, Marta Ximena Leon, Jose-Manuel Quintero et al.
Psilocybin, a psychedelic drug, is being studied for medicinal use, particularly in adult psychiatry and palliative care. Clinical trials show it may benefit patients with treatment-resistant depression and those in palliative care, often in specialist centers. It acts rapidly by targeting the 5HT2A receptor. Its psychoactive effects are well documented, but their clinical importance is debated. Many questions remain about its efficacy for other conditions and its role in psychotherapy.
CNS Spectrums
January 1, 2025
Emma O’leary, Seetal Dodd, Stephen Stahl
Psychoactive substances like psychedelics, cannabis, and stimulants are being reconsidered for therapeutic use, but their histories in non-medical contexts raise ethical and regulatory challenges. This review examines the ethical issues shaping research and prescribing, highlighting diverse perspectives from Indigenous, philosophical, psychiatric, and user communities. Key concerns include balancing therapeutic benefits against misuse risks, ensuring rigorous science, and addressing sociopolitical factors that influence public perception and policy. The article calls for evidence-based frameworks that prioritize patient safety and recognize social and commercial determinants of health, extending ethics beyond prescribing. It critically assesses the promise and limitations of repurposing these substances for contemporary psychiatric practice.